ModernaTX, Inc.
ModernaTX, Inc.
Explore linked clinical trials.41 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-09 | NCT07513376 | |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 4 | 2026-10-07 | NCT07863635 | |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Neoplasms by Site, Thoracic Neoplasms, autosomal dominant Parkinson disease 4, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT06623422 | |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Squamous Non-small Cell Lung Cancer | Recruiting | Phase 2 | 2026-10-01 | NCT07221474 | |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06833073 | |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 4 | 2026-09-28 | NCT07266558 | |
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | Active, not recruiting | Phase 1 | 2026-09-24 | NCT07737717 | |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT07116616 | |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-18 | NCT06077760 | |
| A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants | Healthy Participants | Recruiting | Phase 1 | 2026-09-15 | NCT06655870 | |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 2 | 2026-09-09 | NCT07808697 | |
| An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-09-08 | NCT03897881 | |
| Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | Solid Tumors | Active, not recruiting | Phase 1 | 2026-09-03 | NCT03313778 | |
| Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 4 | 2026-08-27 | NCT07790523 | |
| A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults | Human Metapneuomovirus (hMPV); Respiratory Syncytial Virus (RSV) | Recruiting | Phase 1 | 2026-08-19 | NCT07764237 | |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Infections, RNA Virus Infections, avian influenza, bird disease, influenza, non-human animal disease, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Active, not recruiting | Phase 3 | 2026-08-11 | NCT07496450 | |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, infectious mononucleosis, leukocyte disorder, lymphatic system disorder, lymphoproliferative syndrome, viral infectious disease | Active, not recruiting | Phase 1 | 2026-08-11 | NCT05831111 | |
| A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | Disease Attributes, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-08-10 | NCT06880549 | |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | DNA Virus Infections, Herpesviridae infectious disease, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, cytomegalovirus infection, herpes simplex infectious disease, skin disorder, skin disorder caused by infection, viral infectious disease | Active, not recruiting | Phase 2 | 2026-08-10 | NCT05683457 | |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) | Bacterial Infections and Mycoses, Borrelia infectious disease, Infections, Lyme disease, bacterial infectious disease, gram-negative bacterial infections, spirochaetales infections, tick-borne infectious disease, vector-borne disease | Active, not recruiting | Phase 2 | 2026-08-03 | NCT07561294 | |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Disease Attributes, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT05533697 | |
| A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, autosomal dominant Parkinson disease 4, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-07-13 | NCT06307431 | |
| Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. | Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 1 | 2026-07-01 | NCT06694753 | |
| A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | Human Metapneumovirus; Respiratory Syncytial Virus | Active, not recruiting | Phase 1 | 2026-06-26 | NCT05743881 | |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 2 | 2026-06-15 | NCT06735248 |